View More View Less
  • 1 Szent Imre Kórház Nefrológia-Hypertonia Profil Budapest Tétényi út 12–16. 1115
  • 2 Corvinus Egyetem, Gazdálkodástudományi Kar Vezetéstudományi Intézet Budapest
  • 3 Semmelweis Egyetem, Általános Orvostudományi Kar Transzplantációs és Sebészeti Klinika Budapest
  • 4 Tüdőgyógyintézet Törökbálint
  • 5 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika, Geriátriai Tanszéki Csoport Budapest
  • 6 Dél-budai Nefrológiai Központ Braun Avitum 1. Sz. Dialízisközpont Budapest
Open access

A szervátültetés hosszú távú eredményességének a megfelelő immunszuppresszív kezelés az alapja. A leggyakrabban alkalmazott cyclosporin és tacrolimus egyaránt a szűk terápiás ablakú készítmények közé tartozik és követőkészítményekkel történő helyettesítésük társadalombiztosítási költségcsökkenéshez csak akkor vezet, ha ezek használata azonos klinikai eredményeket biztosít. A szakirodalomban még nem jelentek meg ezt alátámasztó adatok, viszont a nem orvosi döntésen alapuló készítményváltás során fellépő szövődmények irodalma óvatosságra int. A szerzők elemzésükben a tacrolimus nem szakmai szempontok mentén végzett helyettesítése kapcsán mutatják be a lehetséges orvosi komplikációkat és ezek költségszámítása alapján a remélt megtakarításokkal azonos nagyságrendű kiadásokat. Részletezik továbbá a gyermek transzplantáltakhoz, a cyclosporin és a tacrolimus gyógyszer-interakcióihoz és a gyógyszervérszint és betegellenőrzés ellátási terhéhez kötődő problémákat. A szerzők véleménye szerint az európai transzplantációs társaság szakmai irányelve megfelelő és biztonságos szakmai keretet ad a követőkészítmények alkalmazásával elérhető társadalombiztosítási megtakarítás számára a szervátültetésben. Orv. Hetil., 2012, 153, 1341–1349.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Kalo, Z., Jaray, J., Nagy, J.: Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary. Prog. Transplant., 2001, 11, 188–193.

    Nagy J. , 'Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary ' (2001 ) 11 Prog. Transplant. : 188 -193.

    • Search Google Scholar
  • State Audit Office of Hungary: Report on monitoring organ transplantations, organ donation and alternative treatment. [Állami Számvevőszék: Jelentés a szervtranszplantáció, a donáció és az alternatív kezelések ellenőrzéséről.] http://www.asz.hu/jelentes/1020/jelentes-a-szervtranszplantacio-a-donacio-es-az-alternativ-kezelesek-ellenorzeserol/1020j000.pdf , 2010. [Hungarian]

  • Kerpel-Fronius, S.: Clinical pharmacologic principles of the development and application of follow-on biological medicinal products. [Hasonló biológiai (biosimilar) követőgyógyszerek fejlesztésének és alkalmazásának klinikai farmakológiai elvei.] Orv. Hetil., 2007, 148, 915–921. [Hungarian]

    Kerpel-Fronius S. , 'Clinical pharmacologic principles of the development and application of follow-on biological medicinal products. [Hasonló biológiai (biosimilar) követőgyógyszerek fejlesztésének és alkalmazásának klinikai farmakológiai elvei.] ' (2007 ) 148 Orv. Hetil. : 915 -921.

    • Search Google Scholar
  • Kiss, I.: Biosimilar erythropoiesis stimulating agents – from registration to clinical practice. [Biológiailag hasonló (biosimilar) erythropoesist stimuláló készítmények – a törzskönyvezéstől a klinikai gyakorlatig.] Hypertonia és Nephrologia, 2011, 15, 147–153. [Hungarian]

    Kiss I. , 'Biosimilar erythropoiesis stimulating agents – from registration to clinical practice. [Biológiailag hasonló (biosimilar) erythropoesist stimuláló készítmények – a törzskönyvezéstől a klinikai gyakorlatig.] ' (2011 ) 15 Hypertonia és Nephrologia : 147 -153.

    • Search Google Scholar
  • Sabatini, S., Ferguson, R. M., Helderman, J. H., et al.: Drug substitution in transplantation: a National Kidney Foundation White Paper. Am. J. Kidney Dis., 1999, 33, 389–397.

    Helderman J. H. , 'Drug substitution in transplantation: a National Kidney Foundation White Paper ' (1999 ) 33 Am. J. Kidney Dis. : 389 -397.

    • Search Google Scholar
  • European Medicines Agency C.: Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf , 2010

  • Health Canada: Bioequivalence Requirements: Critical Dose Drugs. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/critical_dose_critique-eng.php , 2006

  • Klintmalm, G. B.: Immunosuppression, generic drugs and the FDA. Am. J. Transplant., 2011, 11, 1765–1766.

    Klintmalm G. B. , 'Immunosuppression, generic drugs and the FDA ' (2011 ) 11 Am. J. Transplant. : 1765 -1766.

    • Search Google Scholar
  • FDA: Therapeutic Equivalence of Generic Drugs – Response to National Association of Boards of Pharmacy. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073224.htm , 1997

  • Kesselheim, A. S., Stedman, M. R., Bubrick, E. J., et al.: Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs, 2010, 70, 605–621.

    Bubrick E. J. , 'Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis ' (2010 ) 70 Drugs : 605 -621.

    • Search Google Scholar
  • Gagne, J. J., Avorn, J., Shrank, W. H., et al.: Refilling and switching of antiepileptic drugs and seizure-related events. Clin. Pharmacol. Ther., 2010, 88, 347–353.

    Shrank W. H. , 'Refilling and switching of antiepileptic drugs and seizure-related events ' (2010 ) 88 Clin. Pharmacol. Ther. : 347 -353.

    • Search Google Scholar
  • Duerden, M. G., Hughes, D. A.: Generic and therapeutic substitutions in the UK: are they a good thing? Br. J. Clin. Pharmacol., 2010, 70, 335–341.

    Hughes D. A. , 'Generic and therapeutic substitutions in the UK: are they a good thing? ' (2010 ) 70 Br. J. Clin. Pharmacol. : 335 -341.

    • Search Google Scholar
  • Schiff, J., Cole, E., Cantarovich, M.: Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephrol., 2007, 2, 374–384.

    Cantarovich M. , 'Therapeutic monitoring of calcineurin inhibitors for the nephrologist ' (2007 ) 2 Clin. J. Am. Soc. Nephrol. : 374 -384.

    • Search Google Scholar
  • Kovarik, J. M., Noe, A., Wang, Y., et al.: Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur. J. Clin. Pharmacol., 2006, 62, 361–366.

    Wang Y. , 'Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus ' (2006 ) 62 Eur. J. Clin. Pharmacol. : 361 -366.

    • Search Google Scholar
  • Roza, A., Tomlanovich, S., Merion, R., et al.: Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation, 2002, 74, 1013–1017.

    Merion R. , 'Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation ' (2002 ) 74 Transplantation : 1013 -1017.

    • Search Google Scholar
  • Carnahan, W., Cooper, T. Y.: Neoral-to-Gengraf conversion in renal transplant recipients. Transplant. Proc., 2003, 35, 1308–1313.

    Cooper T. Y. , 'Neoral-to-Gengraf conversion in renal transplant recipients ' (2003 ) 35 Transplant. Proc. : 1308 -1313.

    • Search Google Scholar
  • Vitko, S., Ferkl, M.: Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int. Suppl., 2010, 115 (Suppl.), S12–S16.

    Ferkl M. , 'Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial ' (2010 ) 115 Kidney Int. Suppl. : S12 -S16.

    • Search Google Scholar
  • Qazi, Y. A., Forrest, A., Tornatore, K., et al.: The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin. Transplant., 2006, 20, 313–317.

    Tornatore K. , 'The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function ' (2006 ) 20 Clin. Transplant. : 313 -317.

    • Search Google Scholar
  • Taber, D. J., Baillie, G. M., Ashcraft, E. E., et al.: Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation, 2005, 80, 1633–1635.

    Ashcraft E. E. , 'Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? ' (2005 ) 80 Transplantation : 1633 -1635.

    • Search Google Scholar
  • Helderman, J. H., Kang, N., Legorreta, A. P., et al.: Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Appl. Health Econ. Health Policy, 2010, 8, 61–68.

    Legorreta A. P. , 'Healthcare costs in renal transplant recipients using branded versus generic ciclosporin ' (2010 ) 8 Appl. Health Econ. Health Policy : 61 -68.

    • Search Google Scholar
  • Hibberd, A. D., Trevillian, P. R., Roger, S. D., et al.: Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. Transplantation, 2006, 81, 711–717.

    Roger S. D. , 'Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients ' (2006 ) 81 Transplantation : 711 -717.

    • Search Google Scholar
  • Leet, A., Richardson, M., Senior, J. A., et al.: Bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients. J. Heart Lung Transplant., 2009, 28, 894–898.

    Senior J. A. , 'Bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients ' (2009 ) 28 J. Heart Lung Transplant. : 894 -898.

    • Search Google Scholar
  • McDevitt-Potter, L. M., Sadaka, B., et al.: A multicenter experience with generic tacrolimus conversion. Transplantation, 2011, 92, 653–657.

    Sadaka B. , 'A multicenter experience with generic tacrolimus conversion ' (2011 ) 92 Transplantation : 653 -657.

    • Search Google Scholar
  • Momper, J. D., Ridenour, T. A., Schonder, K. S., et al.: The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am. J. Transplant., 2011, 11, 1861–1867.

    Schonder K. S. , 'The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function ' (2011 ) 11 Am. J. Transplant. : 1861 -1867.

    • Search Google Scholar
  • Marfo, K. A. E., Daniel, G.: Clinical outcomes of inadvertent conversion from brand to generic tacrolimus in renal transplant recipients (abstract).; Am. J. Transplant., 2011, 11 (Suppl. 2), abstract 1635.

  • Abdulnour, H. A., Araya, C. E., Dharnidharka, V. R.: Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr. Transplant., 2010, 14, 1007–1011.

    Dharnidharka V. R. , 'Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication ' (2010 ) 14 Pediatr. Transplant. : 1007 -1011.

    • Search Google Scholar
  • Parker, K. W. A.: Transplant coordinators perceived impact of availability of multiple generic immunosuppression therapies on patients, workload and post-transplant maintenance therapy (abstract).; Am. J. Transplant., 2011, 11 (Suppl. 2), abstract 705.

  • Dankó, D., Remport, A., Mór, Z.: Narrow Therapeutic Index drugs – Special considerations of reimbursement policy in transplantation medicine. [Szűk terápiás indexű gyógyszerek közfinanszírozásának speciális kérdései a transzplantációs medicina példáján.] IME, 2012, 11, 10–18. [Hungarian]

    Mór Z. , 'Narrow Therapeutic Index drugs – Special considerations of reimbursement policy in transplantation medicine. [Szűk terápiás indexű gyógyszerek közfinanszírozásának speciális kérdései a transzplantációs medicina példáján.] ' (2012 ) 11 IME : 10 -18.

    • Search Google Scholar
  • European Medicines Agency C.: Guideline on clinical investigation of immunosuppressants for solid organ transplantation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003593.pdf , 2008

  • Bodrogi, J., Kalo, Z.: Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br. J. Pharmacol., 2010, 159, 1367–1373.

    Kalo Z. , 'Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development ' (2010 ) 159 Br. J. Pharmacol. : 1367 -1373.

    • Search Google Scholar
  • Singh, A. K., Narsipur, S. S.: Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange. J. Transplant., 2011, 2011, Article ID 480642.

  • Remport, A., Molnar, M. Z., Ambrus, C., et al.: Impaired renal function is associated with mortality in kidney-transplanted patients. Int. Urol. Nephrol., 2010, 42, 799–809.

    Ambrus C. , 'Impaired renal function is associated with mortality in kidney-transplanted patients ' (2010 ) 42 Int. Urol. Nephrol. : 799 -809.

    • Search Google Scholar
  • Schnitzler, M. A., Johnston, K., Axelrod, D., et al.: Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. Transplantation, 2011, 91, 1347–1356.

    Axelrod D. , 'Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs ' (2011 ) 91 Transplantation : 1347 -1356.

    • Search Google Scholar
  • Gill, J. S., Tonelli, M.: Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. N. Engl. J. Med., 2012, 366, 586–589.

    Tonelli M. , 'Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation ' (2012 ) 366 N. Engl. J. Med. : 586 -589.

    • Search Google Scholar
  • Prendergast, M. B., Gaston, R. S.: Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin. J. Am. Soc. Nephrol., 2010, 5, 1305–1311.

    Gaston R. S. , 'Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation ' (2010 ) 5 Clin. J. Am. Soc. Nephrol. : 1305 -1311.

    • Search Google Scholar
  • Hougardy, J. M., de Jonge, H., Kuypers, D., et al.: The once-daily formulation of tacrolimus: a step forward in kidney transplantation? Transplantation, 2012, 93, 241–243.

    Kuypers D. , 'The once-daily formulation of tacrolimus: a step forward in kidney transplantation? ' (2012 ) 93 Transplantation : 241 -243.

    • Search Google Scholar
  • Alloway, R. R., Isaacs, R., Lake, K., et al.: Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am. J. Transplant., 2003, 3, 1211–1215.

    Lake K. , 'Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants ' (2003 ) 3 Am. J. Transplant. : 1211 -1215.

    • Search Google Scholar
  • Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant., 2009, 9 (Suppl. 3), S1–S155.

    'KDIGO clinical practice guideline for the care of kidney transplant recipients ' (2009 ) 9 Am. J. Transplant. : S1 -S155.

    • Search Google Scholar
  • Uber, P. A., Ross, H. J., Zuckermann, A. O., et al.: Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J. Heart Lung Transplant., 2009, 28, 655–660.

    Zuckermann A. O. , 'Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory ' (2009 ) 28 J. Heart Lung Transplant. : 655 -660.

    • Search Google Scholar
  • Cutler, C., Kesselheim, A., Gabardi, S., et al.: Generic immunosuppressants in hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2011, 17, 285–290.

    Gabardi S. , 'Generic immunosuppressants in hematopoietic cell transplantation ' (2011 ) 17 Biol. Blood Marrow Transplant. : 285 -290.

    • Search Google Scholar
  • Mactier, R., Davies, S., Dudley, C., et al.: Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009–2012). Nephron. Clin. Pract., 2011, 118, (Suppl. 1) c27–c70.

    Dudley C. , 'Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009–2012) ' (2011 ) 118 Nephron. Clin. Pract. : (Suppl. 1) c27 -c70.

    • Search Google Scholar
  • Van Gelder, T.: European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl. Int., 2011, 24, 1135–1141.

    Gelder T. , 'European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs ' (2011 ) 24 Transpl. Int. : 1135 -1141.

    • Search Google Scholar
  • Harrison, J. J., Schiff, J. R., Coursol, C. J., et al.: Generic immunosuppression in solid organ transplantation: A Canadian Perspective. Transplantation, 2012, 93, 657–665.

    Coursol C. J. , 'Generic immunosuppression in solid organ transplantation: A Canadian Perspective ' (2012 ) 93 Transplantation : 657 -665.

    • Search Google Scholar
  • Danish, A. M.: Generic substitution terminated for oral medicines containing cyclosporine or tacrolimus. http://laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/news/generic-substitution-terminated-for-oral-tacrolimus , 2011